Ipilimumab vs Metoprolol Succinate
## Ipilimumab vs Metoprolol Succinate: Overview
This comparison examines the pharmacological differences between **Ipilimumab** and **Metoprolol Succinate**.
## Mechanism of Action
**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
## Pharmacokinetics
**Half-life**: Ipilimumab — 14.7 days; Metoprolol Succinate — N/A.
## Chemical Properties
**Type**: Ipilimumab — Antibody; Metoprolol Succinate — Small molecule.